Accelerate Diagnostics - AXDX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.00
  • Forecasted Upside: 36.99%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.73
▼ -0.01 (-1.35%)

This chart shows the closing price for AXDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Accelerate Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXDX

Analyst Price Target is $1.00
▲ +36.99% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Accelerate Diagnostics in the last 3 months. The average price target is $1.00, with a high forecast of $1.00 and a low forecast of $1.00. The average price target represents a 36.99% upside from the last price of $0.73.

This chart shows the closing price for AXDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Accelerate Diagnostics. This rating has held steady since March 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
8/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/2/2022William BlairReiterated RatingOutperformLow
5/17/2022Craig HallumLower TargetUnderperform$1.00High
3/9/2022William BlairReiterated RatingOutperformHigh
3/9/2022Craig HallumDowngradeBuy ➝ Hold$5.00High
1/14/2022Craig HallumLower Target$12.00 ➝ $9.00Medium
5/10/2021Piper SandlerLower TargetOverweight$12.00 ➝ $9.00High
11/6/2020Piper SandlerLower TargetOverweight$18.00 ➝ $15.00High
10/7/2020BTIG ResearchInitiated CoverageNeutralMedium
8/10/2020Piper SandlerBoost TargetOverweight$14.00 ➝ $18.00Medium
8/7/2020Craig HallumUpgradeHold ➝ Buy$20.00High
5/11/2020Piper SandlerLower TargetOverweight$16.00 ➝ $14.00Medium
1/14/2020Piper SandlerBoost TargetOverweight$16.00 ➝ $20.00High
9/27/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$16.00High
8/9/2019Piper Jaffray CompaniesLower TargetOverweight ➝ Positive$22.00 ➝ $19.00High
5/12/2019BTIG ResearchReiterated RatingHoldHigh
2/20/2019Piper Jaffray CompaniesBoost TargetIn-Line ➝ Overweight$22.00High
1/11/2019Piper Jaffray CompaniesLower TargetOverweight$17.00High
11/7/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$25.00 ➝ $16.00High
8/7/2018Piper Jaffray CompaniesReiterated RatingBuy$24.00High
5/24/2018Craig HallumInitiated CoverageHold$25.00Medium
2/18/2018BTIG ResearchReiterated RatingHoldMedium
(Data available from 1/29/2018 forward)

News Sentiment Rating

-0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/3/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/1/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/29/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Accelerate Diagnostics logo
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Read More

Today's Range

Now: $0.73
Low: $0.72
High: $0.76

50 Day Range

MA: $0.72
Low: $0.51
High: $0.96

52 Week Range

Now: $0.73
Low: $0.46
High: $3.74

Volume

97,822 shs

Average Volume

240,408 shs

Market Capitalization

$59.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Accelerate Diagnostics?

The following equities research analysts have issued stock ratings on Accelerate Diagnostics in the last twelve months: Craig Hallum, StockNews.com, and William Blair.
View the latest analyst ratings for AXDX.

What is the current price target for Accelerate Diagnostics?

1 Wall Street analysts have set twelve-month price targets for Accelerate Diagnostics in the last year. Their average twelve-month price target is $1.00, suggesting a possible upside of 37.0%. Craig Hallum has the highest price target set, predicting AXDX will reach $1.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $1.00 for Accelerate Diagnostics in the next year.
View the latest price targets for AXDX.

What is the current consensus analyst rating for Accelerate Diagnostics?

Accelerate Diagnostics currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AXDX, but not buy more shares or sell existing shares.
View the latest ratings for AXDX.

What other companies compete with Accelerate Diagnostics?

How do I contact Accelerate Diagnostics' investor relations team?

Accelerate Diagnostics' physical mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company's listed phone number is (520) 365-3100 and its investor relations email address is [email protected] The official website for Accelerate Diagnostics is acceleratediagnostics.com. Learn More about contacing Accelerate Diagnostics investor relations.